CA2579017A1 - Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes - Google Patents

Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes Download PDF

Info

Publication number
CA2579017A1
CA2579017A1 CA002579017A CA2579017A CA2579017A1 CA 2579017 A1 CA2579017 A1 CA 2579017A1 CA 002579017 A CA002579017 A CA 002579017A CA 2579017 A CA2579017 A CA 2579017A CA 2579017 A1 CA2579017 A1 CA 2579017A1
Authority
CA
Canada
Prior art keywords
fluoro
pyrimidinediamine
hydroxyphenyl
pyrimidine
methylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002579017A
Other languages
English (en)
Inventor
Tushar P. Shah
Shahin Sanjar
Pamela Weir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma Ag
Tushar P. Shah
Shahin Sanjar
Pamela Weir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag, Tushar P. Shah, Shahin Sanjar, Pamela Weir filed Critical Altana Pharma Ag
Publication of CA2579017A1 publication Critical patent/CA2579017A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
CA002579017A 2004-09-10 2005-09-08 Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes Abandoned CA2579017A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60854304P 2004-09-10 2004-09-10
US60/608,543 2004-09-10
PCT/EP2005/054470 WO2006027378A1 (fr) 2004-09-10 2005-09-08 Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes

Publications (1)

Publication Number Publication Date
CA2579017A1 true CA2579017A1 (fr) 2006-03-16

Family

ID=35456025

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002579017A Abandoned CA2579017A1 (fr) 2004-09-10 2005-09-08 Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes

Country Status (5)

Country Link
EP (1) EP1791538A1 (fr)
JP (1) JP2008512429A (fr)
AU (1) AU2005281736A1 (fr)
CA (1) CA2579017A1 (fr)
WO (1) WO2006027378A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136995A2 (fr) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibiteurs de la syk protéine kinase
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) * 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
RU2697712C2 (ru) 2011-04-22 2019-08-19 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
EP2782579B1 (fr) 2011-11-23 2019-01-02 Portola Pharmaceuticals, Inc. Inhibiteurs de de la pyrazine kinase
BR112015007217A2 (pt) * 2012-10-19 2017-08-08 Hoffmann La Roche compostos e usos do composto
EP3043798A4 (fr) * 2013-09-13 2017-04-12 Hetero Research Foundation Compositions pharmaceutiques de roflumilast et leur procédé de préparation
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016100308A1 (fr) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Procédés de mesure de l'inhibition de la kinase à terminaison n c-jun dans la peau
ES2877642T3 (es) 2014-12-16 2021-11-17 Signal Pharm Llc Formulaciones de 2-(terc-butilamino)-4-((1R,3R,4R)-3-hidroxi-4-metilciclohexilamino)-pirimidin-5-carboxamida
CA2975260A1 (fr) 2015-01-29 2016-08-04 Signal Pharmaceuticals Llc Isotopologues de 2-(tert-butylamino)-4-((1r,3r,4r) -3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
MX2018001004A (es) 2015-07-24 2018-06-07 Celgene Corp Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2308821T3 (es) * 1997-12-15 2008-12-01 Astellas Pharma Inc. Nuevos derivados de pirimidin-5-carboxamida.
CA2427814C (fr) * 2000-11-07 2009-06-02 Merck & Co., Inc. Combinaison d'un inhibiteur de pde4 et d'un antagoniste des leucotrienes dans le traitement de troubles respiratoires et bronchiques
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses

Also Published As

Publication number Publication date
WO2006027378A1 (fr) 2006-03-16
EP1791538A1 (fr) 2007-06-06
JP2008512429A (ja) 2008-04-24
AU2005281736A1 (en) 2006-03-16

Similar Documents

Publication Publication Date Title
CA2579017A1 (fr) Inhibiteur de roflumilast et de syk combine et procedes d'utilisation associes
US20080027034A1 (en) Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof
US20070167496A1 (en) Roflumilast and glycopyrronium combination
US20040235807A1 (en) Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
TWI396541B (zh) 用於治療呼吸疾病之新穎藥物組合
JP2007518755A (ja) モノアミン神経伝達物質再取り込み阻害剤及びｎ−メチル−ｄ−アスパラギン酸（ｎｍｄａ）受容体アンタゴニストを含む医薬組成物
US20050232871A1 (en) Use of compounds in a dry powder inhaler
EP2359826B1 (fr) Combinaison d'un inhibiteur de la HMG-CoA reductase rosuvastatine avec un inhibiteur de la phosphodiesterase 4, tel que roflumilast, roflumilast-N-oxyde, pour le traitement de maladies pulmonaires inflammatoires
AU2017379247A1 (en) Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy
JP2010526837A (ja) 抗不眠症組成物および方法
KR20190099245A (ko) Task-1 및 task-3 채널 억제제를 함유하는 제약 투여 형태, 및 호흡 장애 요법에서의 그의 용도
US20070185067A1 (en) Ciclesonide and glycopyrronium combination
AU2008259864B2 (en) Methods and compositions for administration of Oxybutynin
EP1670482A1 (fr) Utilisation de ciclesonide dans le traitement de maladies respiratoires
WO2013081565A1 (fr) Compositions pharmaceutiques comportant du roflumilast et de la terbutaline
JP2005524666A5 (fr)
WO2023122473A2 (fr) Traitement par gel de la perte de goût et d'odeur
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
CN101247810A (zh) 催眠药与R(+)-α-(2,3-二甲氧基-苯基)-1-[2-(4-氟苯基)乙基]-4-哌啶甲醇的组合及其治疗应用
JP2007008815A (ja) Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とする呼吸器疾患治療剤
WO2002019995A2 (fr) Utilisation d'une combinaison pharmaceutique
AU2002330687A1 (en) Inhalation compositions comprising tricyclis 5,6-dihydro-9H-pyrazolo (3,4-c)-1,2,4-triazolo (4,3-alpha) pyridines

Legal Events

Date Code Title Description
FZDE Dead